Back to search results

HCC Liver-Link Intervention for Liver Cancer

This study is testing a support program called HCC Liver-Link for Black patients with hepatocellular carcinoma (HCC), a type of liver cancer. The program aims to reduce differences in care by offering patient education about HCC, screening for social needs and substance use with referrals to help, and easier access to specialized cancer care. We are looking for 40 Black patients, aged 18 to 75, who meet specific criteria for their liver cancer. The study will compare patients who receive the HCC Liver-Link program to those who receive usual care. We will follow participants for up to 6 months to see if the program helps them get on the liver transplant waitlist or have surgery sooner.

Study design
This is a pilot study that will randomly assign 40 Black patients to either receive the HCC Liver-Link intervention or usual care.
What's involved
Participants will be followed for 6 months or until they are waitlisted for a liver transplant.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 6 months after enrollment or until liver transplant waitlisting.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06728293

Effect of the HCC Liver-Link Intervention

Recruiting
NAAges 18–75InterventionalTreatment
Indiana University
~40 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Liver Link

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to waitlist
Measured over Up to 6 months post-enrollment
+3 more outcomes measured

Conditions

HCC
Racial Disparities

Explore related trials

Hepatocellular Carcinoma

NCT06728293

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Indiana University School of Medicine

    Indianapolis, Indianastudy coordinator listed

    Recruiting

  • Johns Hopkins University

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Savannah Yarnelle
[email protected]
(317) 278-6424
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

One Class 5 lesion greater than 5 cm and less than or equal to 8 cm
two or three Class 5 lesions that meeting all of the following
At least one lesion greater than 3cm
Each lesion less than or equal to 5 cm, and
A total diameter of all lesions less than or equal to 8cm
Four or five Class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm.
Between 18-75 years old
Have no more than two visits with an HCC-related provider
Able to read, write, and speak English
Any 1 of the following:
Self-report as Black race (can be multiple races as long as 1 is Black)
Self-report as insured by Medicaid (+/- Medicare)
SVI (Social vulnerability index) \>= .75
Unmarried

Exclusion

Lacks capacity to provide informed consent, including those with stage 2 HE or higher at the time of consent.
Age over 75
Last transthoracic echocardiogram with EF\<40% (OK if no prior echo)
BMI over 50
Patients who, in the investigator's judgment, are unlikely to ever be eligible for liver transplantation or resection at the time of enrollment, with reason documented
Prior history of any solid organ transplant
Non-skin cancer malignancies other than hepatocellular carcinoma in past 2 years unless approved by PI (i.e. cervical cancer, early prostate cancer)
Patients who have undergone resection or waitlisted
Patients near completion of transplant evaluation, PI to determine utility of intervention.

What this trial measures

  • Time to waitlistUp to 6 months post-enrollment

    Days from study enrollment to liver transplant waitlisting, assessed using OTTR.

  • Time to resectionUp to 6 months post-enrollment

    Days from study enrollment to surgical resection, assessed using EMR.

  • Waitlisting or ResectionUp to 6 months post-enrollment

    Proportion of participants who achieve liver transplant waitlisting or surgical resection, assessed using EMR and OTTR

  • Time to DeathUp to 6 months post-enrollment

    Days from study enrollment to death, assessed using EMR and OTTR.